Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin Pharmaceutical Inc.

www.bmrn.com

Latest From BioMarin Pharmaceutical Inc.

China Clears First Coronavirus Vaccine Trial

Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.

Coronavirus COVID-19 Clinical Trials

Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development

Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.

Research & Development Coronavirus COVID-19

UK: NICE Wins Argument Over Appraisal Of BioMarin Rare Disease Drug

A decision by England’s High Court to reject claims that HTA body NICE acted unlawfully when evaluating BioMarin’s PKU treatment has quashed hopes that NICE’s Highly Specialized Technologies program will become more widely used to evaluate rare disease treatments. Lawyers representing a PKU patient are planning to appeal the judgement.

Europe United Kingdom

BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?

Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.

Commercial Companies
See All

Company Information

UsernamePublicRestriction

Register